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 In this issue of  Kidney International , 
 Perico  et al. 1 report that treatment with 
RWJ-676070, a dual V 1a and V 2 arginine 
vasopressin receptor antagonist (V 1 /
 V 2 RA), initiated 3 weeks after 5 / 6 
nephrectomy, signifi cantly lowers blood 
pressure, proteinuria, and glomeruloscle-
rosis in rats. Combined treatment with 
RWJ-676070 and an angiotensin-convert-
ing enzyme inhibitor (ACEI) or an angi-
otensin II type 1 receptor blocker (ARB) 
has eff ects on proteinuria, renal function, 
and structure that are numerically, but not 
significantly, greater than those of an 
ACEI or an ARB alone. Th e authors sug-
gest that non-peptide arginine vasopressin 
(AVP) receptor antagonists could be reno-
protective in patients with proteinuric 
chronic kidney disease (CKD). 
 Th e identifi cation of a common path-
way of progressive renal damage, regard-
less of the initiating injury, achieved by 
research in animal models of nondiabetic 
CKD (5 / 6 nephrectomy) and diabetic 
CKD (streptozotocin-induced diabetes 
mellitus) has been one of the major 
achievements in nephrology. 2 Th is path-
way includes reductions in aff erent and, 
to a lesser degree, eff erent arteriolar tone; 
increases in single-nephron perfusion, 
glomerular capillary hydraulic pressure, 
and filtration rate; resetting of tubu-
loglomerular feedback, allowing persist-
ent glomerular hyperfi ltration; and failure 
of autoregulation, exposing glomerular 
capillaries to systemic hypertension . Th e 
superiority of ACEIs and ARBs in treating 
glomerular capillary hypertension, as 
compared with antihypertensive agents 
that mainly dilate preglomerular vessels 
or activate the renin – angiotensin system, 
has established the central role of angi-
otensin II in this pathway. In addition, 
angiotensin II exerts non-hemodynamic 
effects on vascular smooth muscle, 
endothelial and mesangial cells, podo-
cytes, and tubular epithelial and intersti-
tial cells that contribute to CKD 
progression. 
 Although under-recognized, a large 
body of evidence suggests that AVP con-
tributes to nondiabetic and diabetic CKD 
progression. Plasma AVP levels are 
increased in animal models and patients 
with nondiabetic CKD, in animal models 
of streptozotocin-induced and genetic 
diabetes mellitus, and in patients with 
type 1 and type 2 diabetes mellitus. 3,4 
Plasma levels of copeptin, a surrogate 
marker derived from the C-terminal por-
tion of the AVP precursor, are inversely 
correlated with glomerular fi ltration rate 
(GFR). 5 Suppression of AVP by increasing 
water ingestion reduces blood pressure, 
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 Perico  et al. report that a dual arginine vasopressin (AVP) V 2 and V 1a 
receptor antagonist lowers blood pressure, proteinuria, and 
glomerulosclerosis in 5 / 6 nephrectomized rats, pointing to its potential 
value in the treatment of chronic kidney disease (CKD). AVP likely 
contributes to CKD progression by its effects on renal hemodynamics, 
blood pressure, and mesangial and / or epithelial cells, but the relative 
contributions of V 2 and V 1a receptors and potential usefulness of V 2 and 
V 1a receptor antagonists remain ill defined. 
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proteinuria, renal hypertrophy, glomeru-
losclerosis, and tubulointerstitial fi brosis 
in 5 / 6 nephrectomized rats. 6,7 Compensa-
tory renal hypertrophy and CKD progres-
sion following 5 / 6 nephrectomy are 
attenuated in Brattleboro rats, which can-
not secrete AVP, although a study of 
shorter duration (3 versus 13 weeks) did 
not detect this eff ect. 8,9 Brattleboro rats 
with diabetes mellitus exhibit no or mark-
edly reduced glomerular hyperfi ltration, 
albuminuria, and renal hypertrophy com-
pared with wild-type controls. 4 These 
observations seem to contradict a  post hoc 
analysis of the Modification of Diet in 
Renal Disease (MDRD) study in which an 
association between high urine volumes 
and rates of GFR decline was thought to 
refl ect a deleterious eff ect of increased 
water intake on disease progression. 10 
However, it is impossible to conclude from 
this analysis whether high urine fl ow rate 
was a cause or a consequence of GFR 
decline, or whether another independent 
factor infl uenced the two variables simul-
taneously. Furthermore, this association 
is not unexpected, since defective urine-
concentrating capacity is a manifestation 
of CKD. In the study by Perico  et al. , 1 
urine output more than doubled in the 5 / 6 
nephrectomized as compared with the 
control rats and did not increase further 
following V 1a / V 2 RA administration, pos-
sibly because of AVP-resistant downregu-
lation of aquaporin-2 and -3, as well as 
downregulation of aquaporin-1. 11 
 Like angiotensin II, AVP has eff ects on 
glomerular hemodynamics, arterial 
blood pressure, and non-hemodynamic 
renal mechanisms. AVP acts on three G 
protein-coupled receptors: V 2 (cyclic 
adenosine monophosphate (cAMP ) sec-
ond messenger) and V 1a and V 1b (also 
called V 3 ) (calcium second messenger). 
In the kidney, V 2 receptors are found in 
the medullary thick ascending limb of 
Henle (TAL), macula densa, connecting 
tubule, and cortical and medullary col-
lecting ducts, and to a lesser extent in 
the cortical TAL and distal convoluted 
tubule ( Figure 1 ). 12 Contrary to previ-
ous belief, a recent comparative study 
has shown similar patterns of V 2 recep-
tor expression in the rat, mouse, and 
see original article on page 960
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 probably due to suppression of tubu-
loglomerular feedback, possibly caused 
by enhanced urea recycling and / or 
sodium chloride reabsorption in the TAL, 
lowering the sodium concentration at the 
macula densa. Th ese eff ects, which are 
more marked in juxtamedullary neph-
rons, may be responsible for functional 
and structural diff erences between super-
fi cial and deep nephrons. 18 Urine-con-
centrating activity and GFR (or renal 
blood fl ow) are also correlated in healthy 
human volunteers during low and high 
hydration. 19 AVP administration to 
water-loaded healthy volunteers induces 
parallel increases in creatinine clearance 
and urine osmolality. 20 Conversely, 
administration of V 2 RA aft er dehydration 
induces a fall in creatinine clearance. 
Compelling arguments have been made 
linking increased levels of AVP and urine-
concentrating activity to the increased 
risk for CKD progression associated with 
human TAL and collecting duct, and of 
AVP-dependent NaK2Cl cotransporter 
phosphorylation in TAL cells from rats 
and rabbits. 12 V 1a receptors are found in 
the renal vasculature from the interlob-
ular arteries to the eff erent arterioles 
and vasa recta, mesangial cells, macula 
densa, and collecting-duct principal and 
  -intercalated cells. 13,14 Th e localization 
and function of V 1b receptors in the kid-
ney, possibly in the inner medullary col-
lecting duct, are not well characterized. 
 Although RWJ-676070, the compound 
used by Perico  et al. , 1 is a dual V 1a / V 2 RA, 
it has higher affi  nity for rat V 2 than for V 1a 
receptors ( K i  16 and 86 nM, respec-
tively). 15 Previous studies had shown that 
V 2 RA or V 1a RA or both in combination 
have a renoprotective eff ect, suggesting 
that both receptors contribute to CKD 
progression ( Table 1 ). Nevertheless, the 
specificity of these antagonists is not 
 absolute. One study showing that the V 2 
receptor agonist 1-deamino-8 -D- arginine 
AVP (DDAVP), but not AVP, worsens 
proteinuria and renal insuffi  ciency in 5 / 6 
nephrectomized Brattleboro rats even 
raised the possibility that V 1a eff ects of 
AVP could afford a relative protection 
against deleterious V 2 eff ects. Th erefore, 
the relative contributions of V 2 and V 1a 
receptors to, and potential usefulness of 
V 2 and V 1a receptor antagonists for the 
treatment of CKD remain ill-defi ned. 
 Strong experimental evidence supports 
the hypothesis that the V 2 -mediated 
urine-concentrating activity is mainly 
responsible for the renal hemodynamic 
eff ects of AVP ( Figure 1 ). 16,17 A positive 
correlation between urine osmolality and 
GFR was observed (only when urine 
osmolality was equal to or above that of 
plasma) in conscious rats when urine-
concentrating activity was increased by a 
constant infusion of DDAVP or reduced 
by increasing water intake. This is 
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 Figure 1  |  Mechanisms of vasopressin effects on the kidney.  ( a ) Segmental distribution of AVP V 1a receptor. AVP, acting on V 1a receptors in the macula 
densa, regulates renin secretion; acting on V 1a receptors in the vasa recta, it reduces blood flow to the inner medulla and minimizes solute escape from 
the medullary interstitium; and acting on V 1a receptors on the luminal side of collecting-duct principal cells, it stimulates synthesis of prostaglandins 
that attenuate V 2 -mediated antidiuretic action and inhibit sodium transport. (Adapted from refs. 13, 14, and 31 .) ( b ) Segmental distribution of AVP 
V 2 receptor. AVP, acting on V 2 receptors, contributes to urinary concentration by inserting aquaporin-2 (AQP-2 ) into the apical cell membrane of 
collecting-duct principal cells within minutes and upregulating  AQP-2 gene expression in the longer term; activating UT-A1 and UT-A3 in the terminal 
part of the inner medullary collecting duct; stimulating epithelial sodium channel (ENaC) sodium transport in cortical and outer medullary collecting 
ducts; and increasing NaK2Cl  cotransporter expression and sodium reabsorption in the thick ascending limb of the loop of Henle. (Adapted from ref. 
12.) ( c ) Vascular and tubular routes of urea recycling within the kidney. Only a long loop of Henle is depicted, for simplicity. Urea delivery to the inner 
medulla and transit in ascending vasa recta are shown in green. The pathways allowing urea to return to the inner medulla are indicated by red arrows 
for the vascular route and by blue arrows for the tubular route. (Adapted from ref.  38 ) AA, arcuate artery; aa, afferent arteriole; AVR, ascending vasa 
recta; C, cortex; CCD, cortical collecting duct; CNT, connecting tubule; CTAL, cortical thick ascending limb of Henle; DCT, distal convoluted tubule; 
DVR, descending vasa recta; ea, efferent arteriole; ILA, interlobular artery; IM, inner medulla; IS, inner stripe of the outer medulla; M, mesangium; 
MCD, medullary collecting duct; MD, macula densa; MTAL, medullary thick ascending limb of Henle; OS, outer stripe of the outer medulla; UT-A1 / A3, 
vasopressin-regulated urea transporters A1 / A3; UT-A2, urea transporter A2; UT-B, urea transporter B.  
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high protein intake, male gender, and 
black race. 21 – 23 
 Under physiological conditions, the 
renal vasculature and total renal blood 
fl ow are relatively insensitive to the action 
of AVP on V 1a receptors, possibly because 
of shear stress–mediated release of nitric 
oxide. 24 A renal vasoconstrictor response 
to AVP is observed only with very high 
local concentrations or in pathological 
conditions such as congestive heart failure 
with simultaneous activation of the renin –
 angiotensin and sympathetic nervous sys-
tems. Under physiological conditions, 
however, AVP has a signifi cant eff ect on 
the medullary circulation. 25 At physiolog-
ical concentrations (10   −  12 to 10   −  11  M), 
AVP contracts eff erent arterioles isolated 
from rabbit kidneys, whereas it has no 
eff ect on aff erent arterioles. 26  Development 
of diabetes insipidus in dogs is associated 
with eff erent arteriolar dilation. 27 Admin-
istration of a V 1 antagonist to euvolemic 
anesthetized rats lowers GFR and fi ltra-
tion fraction with no change in renal 
blood fl ow, presumably by blocking the 
eff ect of the anesthesia-induced AVP ele-
vation on the eff erent arterioles. 28 Admin-
istration of a V 1a receptor antagonist to 
patients with non-insulin-dependent dia-
betes mellitus is also associated with a 
decrease in GFR and fi ltration fraction. 29 
 Th e renal hemodynamic eff ects of AVP 
may also be due to its eff ects on the renin –
 angiotensin system. AVP could potentially 
stimulate renin secretion directly via acti-
vation of V 2 receptors or indirectly through 
reduction in sodium concentration at the 
macula densa. 12 Indeed, DDAVP-induced 
increases in urine albumin excretion are 
accompanied by an increase in plasma 
renin activity in humans and are prevented 
by ACEIs in rats. 30 V 1a receptors are coex-
pressed with neuronal nitric oxide syn-
thase and / or cyclic oxygenase-2 in the 
macula densa and distal tubules and may 
control renin secretion by stimulation of 
production of nitric oxide and / or prostag-
landin E 2 . 31 Stimulation of renin secretion, 
along with suppression of tubuloglomeru-
lar feedback, may lead to glomerular 
hyperfi ltration, albuminuria, renal hyper-
trophy, and tubulointerstitial disease. 
 Th e eff ects of AVP on blood pressure are 
complex. V 1a eff ects on vascular smooth 
muscle and medullary renal blood fl ow 32 
and V 2 eff ects enhancing   - and   -epithelial 
sodium channel (ENaC) expression and 
ENaC function in the cortical collecting 
duct 33 increase blood pressure. On the other 
 Table 1  Studies ascertaining eff ects of V 2 and / or V 1a agonism or antagonism on chronic kidney disease progression 
 Study a  Drug  Class  Animal model  Treatment duration  Outcome 
 Okada  et al. , 1994  OPC-21268 or 
OPC-31260 or both 
 V 1a RA, V 2 RA  DOCA-salt- and 
adriamycin-treated rats 
 2 – 6 wk  All reduced BP rise, 
V 1a RA / V 2 RA ameliorated 
histology 
 Okada  et al. , 1995  OPC-21268 or 
OPC-31260 or both 
 V 1a RA, V 2 RA  Uninephrectomized 
DOCA-salt hypertensive rats 
 6 – 10 wk (starting at 
surgery or 4 wk later) 
 V 2 RA or V 1a RA / V 2 RA 
reduced BP rise 
 Okada  et al. , 1995  OPC-21268 or 
OPC-31260 or both 
 V 1a RA, V 2 RA  5 / 6 nephrectomized 
spontaneously 
hypertensive rats 
 10 wk (starting at 
surgery) 
 V 1a RA or V 1a RA / V 2 RA 
reduced BP rise, proteinuria, 
and arteriolosclerosis 
 Okada  et al. , 1996  OPC-21268 or 
OPC-31260 or both 
 V 1a RA, V 2 RA  Adriamycin-treated rats  5 – 7 wk  All reduced proteinuria and 
histological alterations 
 Kurihara  et al. , 1996  OPC-21268  V 1a RA  Uninephrectomized 
spontaneously 
hypercholesterolemic rats 
 9 wk  V 1a RA reduced BP and 
glomerular sclerosis and 
improved renal function 
 Bouby  et al. , 1999  DDAVP  V 2 R agonist  5 / 6 nephrectomized 
Brattleboro rats 
 13 wk  DDAVP increased 
proteinuria and worsened 
renal function 
 Naito  et al. , 2001  DDAVP and VP-343  V 2 R agonist, V 2 RA  Sprague-Dawley rats  15 days (VP-343 given 
only on days 5 – 15) 
 DDAVP induced and VP-343 
prevented hypertrophy, 
tubular dilatation, and 
interstitial infi ltration 
 Fernandes  et al. , 
2002 
 DDAVP or SR-121463  V 2 R agonist, V 2 RA  Uninephrectomized 
DOCA-salt hypertensive rats 
 8 wk  DDAVP worsened 
hypertension, albuminuria, 
and histology 
 Bardoux  et al. , 2003  SR-121463  V 2 RA  Streptozotocin-induced 
diabetes mellitus 
 9 wk  V 2 RA prevented rise in 
albuminuria 
 Windt  et al. , 2006  YM-218  V 1a RA  5 / 6 nephrectomized rats  8 wk (starting 2 wk after 
surgery) 
 V 1 RA reduced proteinuria 
and glomerular sclerosis 
 Windt  et al. , 2006  YM-218  V 1a RA  5 / 6 nephrectomized rats  4 wk (starting 6 wk after 
surgery) 
 No eff ect 
 Okada  et al. , 2009  Tolvaptan  V 2 RA  Puromycin aminonucleoside 
nephrosis 
 10 days  V 2 RA reduced proteinuria 
and kidney weight and 
improved renal function 
 Perico  et al. , 2009  RWJ-676070  V 1a / V 2 RA  5 / 6 nephrectomized rats  39 days (starting 3 wk 
after surgery) 
 V 1a / V 2 RA reduced BP rise, 
proteinuria, and glomerular 
sclerosis 
 BP, blood pressure; DDAVP, 1-deamino-8-d-arginine AVP; DOCA, deoxycorticosterone acetate; RA, receptor antagonist. 
 a References available on request. 
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secretion in rat mesangial cells .  Pharmacol Res 
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hand, at high circulating levels of AVP, V 1a 
receptor activation may have an antihyper-
tensive eff ect by inducing synthesis of pros-
taglandins in collecting ducts, inhibiting 
sodium transport, 33 and V 2 receptor activa-
tion may induce nitric oxide synthesis in 
collecting ducts, increasing medullary 
blood fl ow. 32 AVP likely plays a role in salt-
sensitive forms of human and experimental 
hypertension, in which circulating levels of 
AVP and sensitivity to AVP (for example, 
upregulation of V 1a receptors in preglomer-
ular vessels or of V 2 receptors in collecting 
ducts or downregulation of nitric oxide syn-
thase) are increased. Th ese observations are 
likely relevant to the development of hyper-
tension and progression of CKD. 
 Non-hemodynamic eff ects of AVP on 
mesangial-cell proliferation and hypertro-
phy, production of types I and IV collagen 
and fi bronectin, and inhibition of the syn-
thesis of matrix metalloproteinase-2 may 
also contribute to the development of 
glomerulosclerosis and CKD progres-
sion. 34,35 Th e proliferative eff ect of AVP-
induced cAMP accumulation on polycystic 
kidney disease (PKD)-derived epithelial 
cells, which is linked to alterations in intra-
cellular calcium and opposite to the inhib-
itory eff ect observed in wild-type cells, has 
been the basis for  preclinical and currently 
active clinical trials for PKD. 36 A recent 
study has shown that elevated circulating 
AVP sustained (by prolonged osmotic 
stimulation or continuous infusion) for at 
least 3 days induces a proliferative response 
in cells expressing V 2 receptors (TAL and 
collecting duct) that is blocked by V 2 RA 
but not by V 1a RA or V 1b RA, suggesting 
that  prolonged stimulation can convert 
these cells to a cAMP-dependent prolif-
erative phenotype. 37 
 In summary, there is ample evidence 
that AVP contributes to CKD progression. 
To what extent, if any, vasopressin recep-
tor antagonists may be a valuable addition 
to the current treatment of CKD deserves 
attention. 
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